48 pages. Excerpt: The emergence of biologic therapies [also known as biopharmaceuticals and specialty drugs] is straining traditional models of health insurance and health care financing .... For payers and purchasers, the cost of biologics is provoking benefit design changes that include significant cost shifting to patients and attempts to control or limit the cost of these therapeutics to the plan or plan sponsor.  MORE >>